Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
December 06, 2021 07:00 ET
|
Kronos Bio, Inc.
Data in the second half of 2023 could potentially lead to accelerated approvalIf approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit...
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
November 29, 2021 07:00 ET
|
Kronos Bio, Inc.
Initial data demonstrate long plasma half-life and dose-dependent target inhibition Trial is continuing to enroll patients on three-day on, four-day off schedule SAN MATEO, Calif. and CAMBRIDGE,...
Kronos Bio Announces Participation in Upcoming Investor Conferences
November 24, 2021 07:00 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Appoints Roshawn Blunt to Board of Directors
November 11, 2021 16:05 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
November 09, 2021 16:10 ET
|
Kronos Bio, Inc.
Company today announces progression of two discovery programs within its pipeline Highlights from the quarter include presentation of preclinical data on the company’s CDK9 inhibitor KB-0742 at...
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform
November 08, 2021 16:44 ET
|
Kronos Bio, Inc.
Kronos to receive broad access to Tempus’ real-world data and proprietary tools and materials to expand preclinical hypotheses testing capabilities and inform more streamlined clinical trial design ...
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology
November 04, 2021 07:00 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
September 30, 2021 16:36 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations
September 14, 2021 08:00 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 07:00 ET
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...